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Abstract
Background Several fatal cases of bodybuilders, following a
myocardial infarction after long exposure to androgenic-
anabolic steroids (AAS), are reported. In recent years, evi-
dence has emerged of cases of heart failure related to AAS
consumption, with no signs of coronary or aorta atherosclero-
sis. This study aims to further investigate the pathogenesis of
the ventricular AAS-related remodeling performing immuno-
histochemistry (IHC).
Method In order to examine innate immunity activity and
myocytes and endothelial cell apoptosis, IHC analyses were
performed on heart tissue of two cases of bodybuilders who
died after years of supratherapeutic use of metelonone and
nandrolone and where no atherosclerosis or thrombosis were
found, using the following antibodies: anti-CD68, anti-iNOS,
anti-CD163, anti-CD 15, anti-CD8, anti-CD4, anti-HIF1 α,
and in situ TUNEL staining.
Results Results confirm the experimental findings of recent
research that, in the absence of other pathological factors, if
intensive training is combined with AAS abuse, myocytes and
endothelial cells undergo apoptotic alterations. The absence of
inflammatory reactions and the presence of an increased num-
ber of M2 macrophages in the areas of fibrotic remodeling
confirm that the fibrotic changes in the heart are apoptosis-
related and not necrosis-related.
Conclusions In conclusion, the study indicates that, in very
young subjects with chronic hypoxia-related alterations of the
heart, signs of a heart failure in the other organs and a history
of AAS abuse, death can be ascribed to progressive heart
failure due to the direct apoptotic cardiac and endothelial
changes produced by AAS.
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Introduction
Doping is the use of drugs to improve athletic performance. It
is prohibited by anti-doping rules, and a list of the drugs con-
sidered illicit, called The List, is yearly updated by the World
Anti-Doping Agency (WADA).
At present, 48% of all positive doping cases still involves
androgenic-anabolic steroids (AAS) as noted by the WADA in
2014 [1]. Doses 100–1000 times in excess of the therapeutic
range of AASs are commonly used [2]. Side effects are seen in
individuals using or having used high-dosage androgen without
preceding androgen deficiency. The complications are mainly
non-fatal; however, they may lead to severe consequences in-
volving cerebral thrombosis or cardiac infarction [3–5]. Few
fatal cases of bodybuilders, following a myocardial infarction
after long exposure to AAS, are reported [6, 7]. These subjects
often suffer from hyperlipidemia, hypercholesterolemia, and
precocious atherosclerosis secondary to AAS consumption in
supraphysiological doses. Therapeutic uses of AAS are showing
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improvements in aging males for physiologic testosterone re-
placement and as an antianginal in cardiac patients. Therefore,
the correct dose to be used to prevent adverse effects has to be
clarified [8].
In recent years, evidence has emerged of cases with heart
failure, but no signs of coronary or aorta atherosclerosis where
the most important pathological findings have been found, not
only in gross examination but more frequently in histological
samples [9–13].
To further investigate the effects of AAS abuse on myocar-
dial tissue, and the pathogenesis of the ventricular AAS-
related remodeling, we present two cases of bodybuilders
who died after years of supratherapeutic use of metelonone
and nandrolone and where no atherosclerosis or thrombosis
was found. Innate immunity activity and myocytes and endo-
thelial cell apoptosis, which are related to the ventricular re-
modeling as discussed further, were studied histologically on




A 20-year-old bodybuilder, taken ill early in the morning, died
before reaching hospital. Empty packages of Primobolan
Depot (metelonone enantate) and Dynabolon (nandrolone
undecylenate) were found in his apartment. According to
friends of the deceased, he had been taking AAS for a few
years before his death.
Body weight was 87 kg, height 190 cm, and body mass
index (BMI) 28.41.
The post-mortem examination revealed that he had con-
spicuously well-developed skeletal musculature, a low per-
centage of subcutaneous fat tissue, and intense nail cyanosis
of the upper limbs and the ear auricles.
On internal examination, there were no findings suggesting
mechanical trauma or asphyxiation; but the brain and lungs
were heavily congested; the lungs with subpleural petechiae;
and the liver, spleen and kidneys were congested. The heart
showed cardiomegaly (440 g), with hypertrophy and
biventricular dilatation (21mmventricular septum, 19mm left
ventricular free wall, 5 mm right ventricular free wall).
Atrioventricular and semilunar valves were normal. The cor-
onary arteries had a normal origin and course and were patent.
The histological examination revealed, at the interventricular
septum, a hypertrophy of the myocardial fibers, some groups
of elongated and thinned fibers, widespread interstitial and
mainly perivascular fibrosis, hyaline degeneration, and cell
damage. The left ventricle showed extensive focal disarray
with interstitial and replacement fibrosis and widespread in-
terstitial edema; the subendocardial trabecolae showed areas
of colliquative myocytolysis, replacement-type fibrosis, and
extensive perivascular fibrosis, resulting in patches of small
to medium-sized scar areas, areas of fibrofatty replacement,
and a few foci of neovascularization with some instances of
plugged capillaries (Fig. 1a).
The liver showed cholestasis and steatosis. The lungs were
heavily congested, and all lobes revealed multiple areas of
erythrocyte containing alveoli and areas of emphysema alter-
nated with areas of atelectasis. There was intensive congestion
of the kidneys, adrenals, and thyroid.
A chemical-toxicological analysis searching for doping
substances and drug abuse were performed with GC-MS/MS
and showed the presence of AAS in the deceased’s urine (nan-
drolone 5 ng/ml, metelonone (7 ng/ml).
Case 2
A 23-year-old bodybuilder was found dead in his bed.
According to friends and parents, he had been taking AAS
for 2 years before his death and his muscle mass had increased
by about 14 kg.
The body showed hypertrophy of the skeletal musculature.
He was 175 cm tall and weighed 106 kg, with a BMI of 34.61.
The autopsy revealed that the heart showed cardiomegaly
(430 g), with concentric left ventricular hypertrophy (22 mm
ventricular septum, 20 mm left ventricular free wall, 7 mm
right ventricular free wall). Atrioventricular and semilunar
valves were normal. The coronary arteries had a normal origin
and course and were patent. No signs of atherosclerosis were
found in the aorta. The lungs and liver were heavily
congested.
The histologic exam revealed hypertrophied myocytes on
the left ventricle and the interventricular sept, with minimal
myocardial necrosis as seen from the few small foci of gran-
ulation tissue and the extensive interstitial, perivascular, and
subendocardial fibrosis (Fig. 2a). No gross and histologic al-
terations of the other organs were seen, except for congestion.
The chemical-toxicological analysis searching for doping
substances and drug abuse were performed with GC-MS/MS
and showed the presence of AAS in the deceased’s urine (nan-
drolone 7 ng/ml).
Immunohistochemical and in situ TUNEL analyses
Materials and methods
In order to examine innate immunity activity and myocytes
and endothelial cell apoptosis, IHC analyses were performed
on heart tissue using the following antibodies: anti-CD68 for
macrophages (DAKO, Carpinteria, CA), anti-iNOS for M1
macrophages (Abcam, Tokyo, Japan), anti-CD163 for M2
macrophages (Abcam), anti-CD 15 for neutrophils (DAKO),
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anti-CD8 (DAKO), anti-CD4 (DAKO), and anti-HIF1 α
(clone EE122and anti-caspase 3 (Cell Signaling Technology,
Tokyo, Japan). Moreover, in situ TUNEL staining (ApopTag
Peroxidase In Situ Apoptosis Detection Kit, Millipore,
Temecula, CA) was also carried out for the detection of
apoptosis.
Fig. 2 Heart tissue of case 2. a Hypertrophied myocytes of the left
ventricle of case 2 and extensive interstitial, perivascular, and
subendocardial fibrosis (H.E. 20×). b Anti-CD 68-positive macrophages
throughout the heart tissue and in a focal inflammatory infiltrate (arrows)
(anti-CD 68, 10×). c Anti-CD 163-positive M2-type macrophages
throughout the heart tissue (arrows) (anti-CD 163, 10×). d Anti-HIF1-
α-positive endothelial cells in several vessels throughout the sample
(arrows), particularly in the areas of fibrotic replacement (anti-HIF-α,
20×). e TUNEL-positive-stained myocytes (arrow) and positive-stained
endothelial and muscular cells of some arterial vessels (arrow) in a non-
fibrotic areas (TUNEL, 20×). f Caspase 3 positive prevalently in the
endothelial cells of many small-sized vessels (arrows) (anti-caspase 3,
10×)
Fig. 1 Heart tissue of case 1. a Left ventricle showing interstitial and
replacement fibrosis resulting in patches of small to medium-sized scar
areas, areas of fibrofatty replacement, and a few foci of neovasculariza-
tion with some instances of plugged capillaries (H.E. 10×). b A focal
inflammatory infiltrate with few CD8+ lymphocytes (arrows) (anti-
CD8, 40×). c Several macrophages CD68+ throughout the sample
(arrows) and in an inflammatory infiltrate (arrowhead) (anti-CD68,
10×). d Anti-HIF1-α + endothelial cells in vessels (arrowheads) and
leucocytes (white arrow) in an area of fibrotic replacement (anti-HIF1-
α, 10×). e Foci of TUNEL-positive-stained myocytes (double arrows)
and endothelial cells of many vessels (arrows) (in situ TUNEL staining,
10×). fCaspase 3 +myocardial cells (arrows) in areas undergoing fibrotic
changes and in normal heart tissue (double arrows) (anti-caspase 3, 10×).
g Caspase 3+ endothelial and muscular cells of vessels (arrows) (anti-
caspase 3, 10×). h Anti-CD 163 staining shows several M2-type macro-
phages (double arrows) (anti-CD 163, 20×)
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Case 1
IHC staining showed rare focal inflammatory infiltrates with
some CD8+ lymphocytes and several macrophages CD68+
(Fig. 1b, c), while CD15+ neutrophils were scattered in the
myocardium without forming infiltrates, and CD4 lympho-
cytes were absent. Anti-HIF1-α-positive endothelial cells
were found in several vessels of different sizes throughout
the sample, particularly in the areas of fibrotic replacement
(Fig. 1d). TUNEL staining revealed throughout foci of
positive-stained myocytes and positivity of endothelial cells
of many vessels (Fig. 1e). In the areas undergoing myocyte
replacement with fibrotic tissue, vessels showed only some of
the endothelial cells in apoptosis. In the fibrotic areas, no
vessels stained positive, and damaged myocytes were positive
as well as some fibroblasts and monocytes. Caspase 3 stained
positive in many foci of myocardial cells, especially in areas
undergoing fibrotic changes (Fig. 1f) and in endothelial and
muscular cells of several vessels of different sizes (Fig. 1g).
Purkinje cells also stained positive with caspase 3. CD68+
macrophages were present throughout the tissue, increasing
in the areas undergoing fibrotic replacement, whereas in some
areas, focal microinfiltrates were identifiable. Anti-iNOS and
anti-CD 163 staining showed that all macrophages where M2-
type (Fig. 1h), while only rare or none M1-type macrophage
was identifiable.
A sample of deltoid muscle was stained following the
same procedure and showed positivity only to caspase 3
and TUNEL of endothelial and muscular cells of several
arteries.
Case 2
Immunostaining showed few focal inflammatory infil-
trates formed by lymphocytes and CD68+ macrophages
(Fig. 2b). CD68+ cells were present throughout the tis-
sue, and anti-CD 163 staining proved them to be all M2
macrophages (Fig. 2c), while rare M1 i-NOS+ cells were
found in the epicardium and interstitial tissue. CD15+
neutrophils were scattered in the myocardium without
forming infiltrates, and CD4+ lymphocytes were absent.
Anti-HIF1-α-positive endothelial cells were found in sev-
eral vessels throughout the sample, particularly in the
areas of fibrotic replacement (Fig. 2d). TUNEL staining
revealed throughout foci of positive-stained myocytes
and positivity of endothelial and muscular cells of some
different-sized arterial vessels, less in number than in
case 1, especially in the non-fibrotic areas (Fig. 2e).
Caspase 3 was positive prevalently in the endothelial
cells of many small-sized vessels, and in several cells
of the epicardium and interstitial tissue, and in the
Purkinje cells (Fig. 2f).
Control case
The cardiac tissue taken from a 16-year-old youth who had
died after a fall from the height was analyzed as a control case.
The weight of the heart was 220 g, and there was neither
macroscopic anomaly nor injury. No histopathological alter-
ations were found. At the IHC, no presence of CD15+ neutro-
phils was shown, while CD68+ cells were present in all the
tissue and were identified as M2 macrophages without
forming infiltrates (Fig. 3a). No M1 macrophages and no T
lymphocytes were found. TUNEL documented positive
myocytes in the subendocardium, rare myocytes in the myo-
cardium, and several cells in the interstitium. Vessel walls
showed no positivity with TUNEL staining. Caspase 3 was
positive in several cells in the subendocardium tissue and in a
few small vessels and in the Purkinje cells. Positive reactions
for caspase 3 were found in the few myocardiocytes (Fig. 3b).
Discussion
It is of common opinion that cardiac hypertrophy resulting
solely from physical exercise has minimal or no harmful ef-
fects on the heart. This is true even for the most strenuous of
sports. In fact, a non-AAS user athlete who dies due to heart
trouble usually had a pre-existing undiagnosed cardiomyopa-
thy [14]. Most persons who grossly misuse AAS by stacking
with supra-therapeutic doses are bodybuilders although some
weightlifters especially powerlifters may do so. None of these
persons engage in endurance training which is commonly as-
sociated with physiological, i.e. non-pathological cardiac hy-
pertrophy. Certainly when engaging in weight training, these
persons can and often do experience hypoxia especially if they
unwisely breath-hold. Hence, such training should not cause
physiological cardiac hypertrophy and if it occurs as in the
two cases described, it seems reasonable to suggest it is a
direct consequence of administering supra-therapeutic doses
of AAS over an extended period of time and could be consid-
ered to be Bnon-physiological.^
Cardiovascular implications of supraphysiological andro-
gen levels still require further clarification, and concentric left
ventricular hypertrophy is being studied by means of imaging
techniques on living athletes. It has confirmed that use of AAS
may lead to cardiac hypertrophy and has hypothesized a direct
cardiotropic effect [15] associated with a significantly lower
left ventricle ejection fraction and decreased diastolic function
[16] strongly associated with mean dosage and duration [17,
18]. Furthermore, some recent innovative diagnostic tech-
niques, such as pulsed-wave tissue Doppler imaging and
ultrasonic-integrated backscatter cyclic variation analysis
[19] and cardiac magnetic resonance (CMR) [20], document-
ed regional systolic and diastolic dysfunction in AAS users
with respect to AAS non-users or control cases. Angell and
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colleagues [21] could detect pathological alterations of ven-
tricular structure and dysfunction in the hearts of AAS users in
CMR analyses. However, focal cardiac fibrosis, which is al-
most found histopathologically in AAS users, could not be
detected by the use of CMR. Considering from these obser-
vations, CMR analyses would be insufficient for the detection
of focal cardiac fibrosis.
In our study, the morphological features found in the heart
tissue of the cases presented agree with most of those found in
similar cases of death due to anabolic abuse. There are no
signs of atherosclerosis or thrombosis, i.e. focal myocardial
fibrosis, but with foci of contraction band necrosis [9], con-
centric cardiac hypertrophy with focal fibrosis, dilated cardio-
myopathy with patchy myocyte death, eosinophilic myocar-
ditis [10], few small foci of granulation tissue and lymphocyt-
ic infiltration around vessels [11], marked cardiac and renal
hypertrophy and hepatosplenomegaly, with regional myocar-
dial fibrosis and focal myocardial necrosis [12], and acute
cellular necrosis and interstitial fibrosis of the myocardium
[13].
Moreover, the IHC staining performed (caspase 3 and
TUNEL staining) also shows a significant increase in the rate
of cardiomyocyte and endothelial cell apoptosis in AAS
abusers. This feature is common, not only in acute ischemic
hearts, where caspase 9 activation triggers cardiomyocyte and
endothelial cell apoptosis [22], but also in dilated cardiomy-
opathy and heart failure. In these cases, the apoptotic loss of
cardiomyocytes plays an important role in the speed of heart
failure progression [23].This hypothesis has been confirmed
by an experimental study that showed elevated caspase 3 ac-
tivity in the hearts of AAS-treated rabbits compared to control
experiments, suggesting that apoptosis is involved in the in-
duction of norethandrolone-induced cardiac lesions [24].
Moreover, there is evidence of increased cardiomyocyte apo-
ptosis following the transition from compensated hypertrophy
to left ventricle dysfunction [25].
Although caspase 3 is the terminal effector caspase for both
intrinsic (mitochondrial-dependent) and extrinsic (death
receptor ligand-dependent) apoptosis pathways, several stud-
ies underline the important role of mitochondrial pathway in
the apoptosis AAS-related. It is well known that both physio-
logical cell death (apoptosis), and, in some cases, accidental
cell death (necrosis), relies on the liberation of apoptogenic
proteases or protease activators from mitochondria [26]. In
sedentary rats treated with anabolic steroids, hypertrophy
and mitochondria fusion occur, resulting in an increase in
volume and a decrease in mitochondria numbers, whereas
the production of ATP remains the same, thus being propor-
tionally insufficient for the needs of the hypertrophic cell. A
combination of training and anabolic steroid use destroys the
mitochondria triggering a caspase cascade that leads to cell
death by apoptosis [27, 28, 29]. The loss of production in
cellular energy can result in a chronic hypoxia of the cardiac
muscle, also favored by the coronary-spastic action of the
steroids. In these cases, cell death may occur due to apoptosis,
rather than necrosis.
Genetics may also be responsible for some mitochondrial
reactions to training and AAS and could explain why AAS
abusers react in many different ways—some being unaffected,
others only with complications, and others dying [30, 31].
During a steady state, macrophages in the heart show a
gene profiling of M2 and carry out routine repairs and main-
tain tissue integrity. Also, M1 macrophages direct T cells to-
ward Th1-, and M2 macrophages toward Th2-like activities
and are dominant in the first stage of heart injury, i.e. infarc-
tion [32, 33]. In the two cases presented, compared to the
control case, an increased number of macrophages CD68+,
proven to be mature macrophages (M2 differentiation stage),
especially in the myocardium and in focal infiltrations in the
myocardium undergoing fibrosis, were documented, whereas
in the first maturation stage, M1-type macrophages were ab-
sent, indicating that there is no active inflammatory response.
Fig. 3 Heart tissue of the control case. a Anti-CD 163-positive M2-type macrophages sparsely in the tissue without forming infiltrates (arrows). b
Caspase 3-negative endothelial cells in two small vessels (arrowheads) and positive in few apoptotic myocardocytes (arrows) (anti-caspase 3, 20×)
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This feature is found in ischemic hearts in a regenerative
phase, in which cells with a lesser inflammatory phenotype
promoting tissue repair of M2-type macrophages prevail, and
in idiopathic dilated cardiomyopathy, as well as in animal
models of heart failure and remodeling [25].
As well known, apoptosis does not result in an inflamma-
tory stimulus, and this could explain the presence, in our
cases, of CD 15+ neutrophils only scattered throughout the
myocardial tissue, while the presence of few lymphocytes
CD8+ in some foci of macrophages could be tied to their
activity as damaged cell phagocytes. The high number of
M2 macrophages throughout the myocardium, and in foci in
the damaged tissue, necessary for the fagocitation of apoptotic
cells, contributes to the theory of a progressive loss of
myocytes through apoptosis, and through the macrophage
production of stress-activated cytokines that leads to progres-
sive heart failure [25].
An in vitro study revealed an apoptotic steroid- type-de-
pendent effect in human umbilical vein endothelial cells (tes-
tosterone induced 31% of apoptotic cells, norandrostenedione
25%, androstenedione 15%, and nandrolone 18%) and
showed that androgen steroids modulate intracellular levels
of calcium, independent of incubation time or compound
identity, through the alteration of the endothelial homeostasis,
which facilitates early endothelial cell activation responsible
for vascular complications observed frequently in AAS
users [34]. Our results confirm the detrimental action that
AAS exerts on tissue vessel walls. The cardiac tissue of the
two AAS abuse cases, compared to the control case, showed
apoptotic reaction, as shown by TUNEL and anti-caspase 3, in
several vessel endothelial and muscular cells, as well as in the
muscle sample taken in case 1.
Conclusion
There are many difficulties in interpreting the experimental
data from animals (mice and rats) related to AAS abuse, due
to the diversity of substances used, the different sex and age of
the mice/rats, the AAS treatment times, dosages used, type,
scope, and exercise duration [35] . Therefore, verifying these
results in the case of humans is of paramount importance,
since the pathophysiological mechanism of AAS-related
deaths is still obscure in several aspects [36].
In the cases presented, the microscopic findings in the car-
diac tissue confirm the experimental findings of recent re-
search that, in the absence of other pathological factors, if
intensive training is combined with AAS abuse, myocytes
and endothelial cells undergo apoptotic alterations, which
are especially related to mitochondrial damage, as document-
ed by experimental researches. The ATP-related loss of energy
inmyocytes and endothelial cells, and their apoptotic changes,
causes a chronic hypoxia-like condition that leads to the
progressive fibrotic remodeling of cardiac tissue. The absence
of inflammatory reactions, as seen by the immunostainings
performed, and the presence of an increased number of M2
macrophages in the areas of fibrotic remodeling confirm that
the fibrotic changes in the heart are apoptosis-related and not
necrosis-related.
In conclusion, although it concerns only two cases, our
study documents the findings so far showed in experimental
studies, that, in very young subjects with no history of chronic
systemic pathologies, no signs of atherosclerosis, but with
chronic hypoxia-related alterations of the heart, signs of a
heart failure in the other organs and a history of AAS abuse,
death can be ascribed to progressive heart failure due to the
direct apoptotic cardiac and endothelial changes produced by
AAS. As far as we know, this is the first immunohistochem-
ical study on this topic. Obviously, further studies on human
cardiac tissue in doping cases and controls are needed, which
we encourage for a comparison with ours.
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